Evidence map›Paper›PMID 31533734›Full record

ArticleBMC infectious diseases2019

Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis.

Patrizia Künzler-Heule, Sandra Engberg, Manuel Battegay, Axel J Schmidt, Katharina Fierz, Huyen Nguyen, Agnes Kocher, Christiana Nöstlinger, Benjamin Hampel, Marcel Stöckle and 9 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02785666 (A Phase III, Multi-center, Open-label Trial to Investigate the Impact of a Treat, Counsel and Cure Strategy in Men Who Have Sex With Men With Hepatitis C Infection in the Swiss HIV Cohort Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02785666 phase3completednot on this map

A Phase III, Multi-center, Open-label Trial to Investigate the Impact of a Treat, Counsel and Cure Strategy in Men Who Have Sex With Men With Hepatitis C Infection in the Swiss HIV Cohort Study

TypeinterventionalSponsorUniversity of ZurichRan2016 to 2018Enrolled150ConditionsHepatitis C, HIVArmsgrazoprevir/elbasvir, ribavirin, Behavioural Intervention
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 5 countries.

Patrizia Künzler-HeuleNursing Science, Department Public Health, Faculty of Medicine, University of Basel, Bernoullistrasse 28, CH-4056, Basel, Switzerland.
Sandra EngbergNursing Science, Department Public Health, Faculty of Medicine, University of Basel, Bernoullistrasse 28, CH-4056, Basel, Switzerland.
Manuel BattegayDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Axel J SchmidtDivision of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Katharina FierzZurich University of Applied Sciences (ZUAS), Winterthur, Switzerland.
Huyen NguyenDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Agnes KocherNursing Science, Department Public Health, Faculty of Medicine, University of Basel, Bernoullistrasse 28, CH-4056, Basel, Switzerland.
Christiana NöstlingerDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Benjamin HampelDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Marcel StöckleDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Charles BéguelinDepartment of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland.
Julie DelaloyeDepartment of Intensive Care Medicine, University of Lausanne and University Hospital, Lausanne, Switzerland.
Patrick SchmidDivision of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Markus FleppCenter for Infectious Diseases, Klinik im Park, Zurich, Switzerland.
Mathieu RougementPrimary Care Medicine Unit, University Hospital of Geneva, Geneva, Switzerland.
Dominique Laurent BraunDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Jan FehrDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Dunja NiccaNursing Science, Department Public Health, Faculty of Medicine, University of Basel, Bernoullistrasse 28, CH-4056, Basel, Switzerland. dunja.nicca@unibas.ch.ORCID http://orcid.org/0000-0002-4133-8177
Swiss HIV Cohort Study (SHCS)
University of Basel · CHKantonsspital St. Gallen · CHUniversity Hospital of Zurich · CHUniversity of Bern · CHUniversity of Zurich · CHHirslanden Klinik Im Park · CHHochschule Campus Wien · ATUniversity of Pittsburgh · US

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 177499Swiss HIV Cohort Research Foundation 772
6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) is common in men who have sex with men (MSM) with HIV. The Swiss HCVree Trial targeted a micro-elimination by using a treat and counsel strategy. Self-reported condomless anal intercourse with non-steady partners was used as the selection criterion for participation in a counselling intervention designed to prevent HCV re-infection. The purpose of this study was to assess the ability of this criterion to identify men who engaged in other sexual risk behaviours associated with HCV re-infection.

methodsMen who disclosed their sexual and drug- use behaviours during the prior 6 months, at study baseline, were included in the current study. Using a descriptive comparative study design, we explored self-reported sexual and drug-use risk behaviours, compared the odds of reporting each behaviour in men who reported and denied condomless anal intercourse with non-steady partners during the prior year and calculated the sensitivity/specificity (95% CI) of the screening question in relation to the other at-risk behaviours.

resultsSeventy-two (61%) of the 118 men meeting eligibity criteria reported condomless anal intercourse with non-steady partners during the prior year. Many also engaged in other potential HCV transmission risk behaviours, e.g., 52 (44%) had used drugs. In participants disclosing drug use, 44 (37%) reported sexualised drug use and 17 (14%) injected drugs. Unadjusted odds ratios (95% CI) for two well-known risk behaviours were 2.02 (0.80, 5.62) for fisting and 5.66 (1.49, 37.12) for injecting drug use. The odds ratio for sexualised drug use - a potential mediator for increased sexual risk taking - was 5.90 (2.44, 16.05). Condomless anal intercourse with non-steady partners showed varying sensitivity in relation to the other risk behaviours examined (66.7-88.2%).

conclusionsAlthough condomless anal intercourse with non-steady partners was fairly sensitive in detecting other HCV relevant risk behaviours, using it as the only screening criterion could lead to missing a proportion of HIV-positive men at risk for HCV re-infection due to other behaviours. This work also points to the importance of providing access to behavioral interventions addressing other sexual and drug use practices as part of HCV treatment.

trial registrationClinical Trial Number: NCT02785666 , 30.05.2016.

Indexed as

AdultHepatitis CHIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedOdds RatioRisk-TakingSelf ReportSexual BehaviorSubstance-Related DisordersCondomsHepatitis C virusHIVHomosexualityMaleSexual behavior

Identifiers

PMID31533734
PMCPMC6751884
OpenAlexW2974227474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.